Wintergreen India Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.30 M
- Company Age 9 Year, 17 Days
- Last Filing with ROC 31 Mar 2019
- Revenue Growth 17.12%
- Profit Growth -138.21%
- Ebitda 142.83%
- Net Worth -2.34%
- Total Assets -19.52%
About Wintergreen India Pharmaceutical
Wintergreen India Pharmaceutical Private Limited (WIPPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 January 2016 (Nine years 17 days old ). Its registered office is in Coimbatore, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Raju Pari, Chandra Sekaran, Suresh Kumar, and One other member serve as directors at the Company.
Company Details
-
Location
Coimbatore, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232TZ2016PTC022230
-
Company No.
022230
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
29 Jan 2016
-
Date of AGM
30 Sep 2019
-
Date of Balance Sheet
31 Mar 2019
-
Listing Status
Unlisted
-
ROC Code
Roc Coimbatore
Industry
Who are the key members and board of directors at Wintergreen India Pharmaceutical?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raju Pari
|
Director | 29-Jan-2016 | Current |
|
Chandra Sekaran
|
Director | 29-Jan-2016 | Current |
|
Suresh Kumar
|
Director | 29-Jan-2016 | Current |
|
Senthil Kumar
|
Director | 29-Jan-2016 | Current |
Financial Performance of Wintergreen India Pharmaceutical.
Wintergreen India Pharmaceutical Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 17.12% increase. The company also saw a substantial fall in profitability, with a 138.21% decrease in profit. The company's net worth dipped by a decrease of 2.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wintergreen India Pharmaceutical?
Unlock access to Wintergreen India Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Wintergreen India Pharmaceutical?
Unlock and access historical data on people associated with Wintergreen India Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wintergreen India Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wintergreen India Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
